Mesoblast Confirms U.S. Tariff Exemption for Allogeneic Cellular Products, Including Ryoncil® and Revascor®

Mesoblast, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on the status of its products in relation to the U....

April 04, 2025 | Friday | News
Pillar Biosciences Secures U.S. Nationwide Medicare Coverage for oncoReveal® CDx Pan-Cancer NGS Kit

 Pillar Biosciences, Inc., the leader in Decision Medicine™,  announced they have received nationwide Medicare coverage by the Centers fo...

April 04, 2025 | Friday | News
AES Cleanroom Technology Launches Omni ASCENT at INTERPHEX 2025 to Redefine Modular Utility Integration

AES Cleanroom Technology, a leader in modular cleanroom solutions, has officially launched Omni ASCENT at INTERPHEX 2025. The next-generation Off-Site Ma...

April 04, 2025 | Friday | News
NetraMark and Worldwide Clinical Trials Partner to Advance AI-Driven Precision in Global Clinical Trials

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company th...

April 04, 2025 | Friday | News
Thermo Fisher Scientific Launches Krios 5 Cryo-TEM Revolutionizing Structural Biology with Enhanced Throughput and AI Automation

Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Krios™ 5 Cryo-TEM. This next-generati...

April 03, 2025 | Thursday | News
Genentech Reports Phase III MUSETTE Trial Results for Ocrevus® Showing No Additional Benefit from Higher Dose in Relapsing MS

Genentech, a member of the Roche Group, announced  that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...

April 03, 2025 | Thursday | News
Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s Disease Treatment

Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oli...

April 03, 2025 | Thursday | News
Roche Reports Phase III MUSETTE Trial Results Showing No Additional Benefit from Higher Dose of OCREVUS® in Relapsing MS

Roche announced that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OC...

April 03, 2025 | Thursday | News
Cytiva Expands MabSelect Resin Portfolio to Advance Affordable and Scalable mAb Purification

  MabSelect SuRe 70 and MabSelect PrismA X resins to set new standards in affordability and productivity Cytiva's expanded resin portfolio will ...

April 03, 2025 | Thursday | News
Yingli Pharma Receives FDA Clearance to Launch Phase 3 Trial for Linperlisib in Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...

April 02, 2025 | Wednesday | News
DuPont Launches Liveo™ Pharma TPE Ultra-Low Temp Tubing for Demanding Biopharma Processing Needs

  Sterilizable, weldable, sealable thermoplastic elastomer tubing intended for biopharmaceutical processing applications that require low temperature...

April 03, 2025 | Thursday | News
Inventiva Completes Patient Enrollment in Phase 3 NATiV3 Trial for MASH Treatment

Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecule dru...

April 02, 2025 | Wednesday | News
Trump Administration Cuts 10,000 Federal Health Jobs, Sparking National Outcry

Massive Health Workforce Shake-Up: 10,000 Federal Health Agency Employees Face Layoffs Amid Budget Axes Trump administration has begun...

April 02, 2025 | Wednesday | News
FDA Approves Freeze-Dried Formulation of JYNNEOS® for Smallpox and Mpox Prevention

Bavarian Nordic A/S announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and...

April 01, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close